Sepideh Hagvall

Artificial intelligence (AI) is an important driving force that is rapidly transforming health care and pharmaceutical industries in several ways. The vast amount of biomedical data available today poses unique opportunities to develop a repertoire of AI-based models. Although the results from studies using AI for solving biomedical problems are encouraging, there are numerous scientific challenges associated with AI for life science applications that need to be addressed.

This project is one of the three subprojects within the synergy project BioMine - Data-mining for biomarker discovery, selection, and validation. In this subproject we investigate how large-scale biomolecular data can be used to identify specific biomarkers for disease modelling

This project is one of the three subprojects within the synergy project BioMine - Data-mining for biomarker discovery, selection, and validation. In this subproject we investigate how large-scale biomolecular data can be used to identify specific biomarkers for toxicity testing. The project is performed in close collaboration between the University of Skövde, AstraZeneca Gothenburg and Takara Bio Europe.

In the BioMine project (Data-mining for Biomarker Discovery, Selection, and Validation), studies are performed on how large-scale biomolecular data can be mined to enable discovery and validation of multilevel biomarkers in Life Science.

Within AlgorOmics we develop and implement algorithms for integration, visualization, and analysis of large-scale omics data, with applications in stem cell differentiation and drug development.

The advancement in stem cell research over the last decade has now made it possible to generate large quantities of human specialized cells for in vitro applications. Specifically, in the drug discovery and development process this has important implications. The project involves studies of the genetic and molecular basis of hypertrophy and aims to develop new knowledge that can contribute to the development of novel therapies and treatments that can reduce cardiovascular morbidity and mortality.